Analyst
RBC
Equibles does not estimate personal net worth.
Dan Leonard is recorded as Analyst at RBC. Dan Leonard has spoken on 7 earnings calls and 2 other investor events across 6 companies, most recently for Revvity, Inc. on November 3, 2026. Those appearances were for Agilent Technologies, Inc. (A), Repligen Corp (RGEN), Bio-Rad Laboratories, Inc. (BIO), Revvity, Inc. (RVTY), Mettler Toledo International Inc (MTD) and 1 other company. The companies whose calls Dan Leonard spoke on are classified in the Healthcare sector.
“I just wanted to revisit that reagents growth number again. You know, high single digits in total, mid-single digits, that's the bulk. You talked a bunch about end market improvement, but it doesn't seem like the end markets for reagents businesses are growing that fast if you look at comps that have already reported.”
“I'm trying to think further on the sustainability of that double-digit growth rate in pharma. How dependent is double-digit growth in that end market on your CDMO business?”
“Patrick, I would just like to revisit your comments on emerging markets outside of China, that high single-digit growth rate. Can you offer some more color? Is that all volume?”
“I'd like to talk a bit more about the topic of order conversion, specifically in light of that comment, Olivier, that you made that Q2 order strength and filtration fuels your 2027 growth outlook.”
“Just a clarification on those 2030 targets, Olivier. The goal to double revenue by 2030, this BioLife deal is included in that target and not incremental, correct?”
RBC
Analyst
Transcript header (unverified)
Diagnostics & Research · Healthcare
RGEN
Medical Instruments & Supplies · Healthcare
RVTY
Diagnostics & Research · Healthcare
AVTR
Medical Instruments & Supplies · Healthcare
